Trial
NCT00270257
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
National Institute on Drug Abuse (NIDA)
Condition
HIV Infections
Intervention
Buprenorphine/Naloxone
Why stopped
DSMB halted the study due to futility as a result of lower than anticipated HIV incidence rates
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-05